June 18, 2021 8:27am

Quadruple witching is usually accompanied by price volatility, as well as increased trading volume

Pre-open indications: 3 BUY – AGTC, RARE, VYGR; 4 SELLs into Strength - profit: CRSP, EDIT, FATE, NTLA; 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are DOWN -0.59% (-198 points), S&P futures are DOWN -0.55% (-23 point) and NASDAQ futures are DOWN -0.30% (-42 points)

 

U.S. stock futures are falling in early premarket trade on Friday morning

European stocks were relatively flat

Asia-Pacific stocks were mixed

 

Henry’omics:

Friday is on pace to post a losing week after the Federal Reserve’s latest policy update.

Although the Nasdaq ended or was within striking distance of a record high while the Dow posted a fourth straight session of losses.

Thursday's weekly jobless claims report from the Labor Department showed an unexpected increase in initial unemployment filings, underscoring the still-choppy recovery taking place across the U.S.

Sign of the week, 3 biotech <Verve Therapeutics (VERV +86%), Lyell Immunopharma (LYLE -$0.11), iSpecimen (ISPC -$0.85) went public yesterday, only one gained.

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results to date …  https://www.regmedinvestors.com/articles/11628

 

Thursday’s evening’s recap: “the cell and gene therapy sector rallied after a two (2) session flogging. Decliners in the sector were fewer than expected:” … https://www.regmedinvestors.com/articles/11960

  • The Nasdaq closed UP +121.67 points (+0.87%);
  • The IBB closed up +0.49% and XBI closed up +0.59%
  • Sector volume was LOW with 6 of the 23-upside having higher than the 3-month average volume with the volume of 5 of 10-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -0.40 points or -2.20% at 17.75
  • Thursday’s percentage (%) of the 23-upside were +0.17% (QURE) to +6.56% (BLFS) while the 10-downside ranges from -1.07% (RGNX) to -6.92% (BSTG);

Q2/21:

June: 8 positive and 4 negative close

May:  8 positive, 12 negative closes and 1 holiday

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …

Biostage (BSTG) closed down -$0.09 to $1.21 with 735 shares traded after Wednesday’s +$0.089 to $1.30 with 205 shares traded, Tuesday’s -$0.039 to $1.21 with 10,703 shares traded, Monday’s flat at $1.25 with 2,305 shares traded and last Friday’s +$0.04 with 1,395 shares traded to $1.25,

 WHO is trading this ZOMBIE?

Question#`1: Notice the volume numbers per session? WHY the need to “pump, promote and inflate” the share price; does the volume reflects the manipulation to execute the last remaining warrants?

Question#2: Will the annual meeting result in ANY news to/about the future of the company?

Question#3: WHY do I keep writing on BSTG – I was there and then SUDDENLY I wasn’t (there through NO fault of my own other than to UPHOLD the law) and saw WHAT they DID, WERE, KEPT on doing and CONTINUE to do - but, the REAL question to be ANSWERED is WHO is advising them in ALL of these endeavors?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

BUY:

Applied Genetic Technologies (AGTC) closed up +$0.05 to $4.40 and has a positive +$0.05 or +1.14% pre-market indication.

Ultragenyx (RARE) closed down -$1.80 to $95.98 with a positive +$1.02 or +1.06% aftermarket indication.

Voyager Therapeutics (VYGR) closed down -$0.17 to $4.65 with a positive +$0.06 or +1.29% aftermarket indication.

 

SELL into Strength – profit motive:

CRISPR Therapeutics (CRSP) closed up +$3.36 to $127.27 after Wednesday’s +$0.29 to $123.91 and has a positive +$0.13 or +0.10% pre-market indication and a +84.01% 52-week change.

Fate Therapeutics (FATE) closed up +$1.56 to $84.21 with a positive +$2.57 or +3.05% aftermarket indication and a 52-week change of +148.95% - room to sell some of the position.

Editas Medicine (EDIT) closed up +$1.16 to $36.16 after Wednesday’s -$0.10 to $35.00 and Tuesday’s -$3.43 to $35.19 with a negative -$0.06 or -0.17% indication.

Intellia Therapeutics (NTLA) closed down -$2.74 to $76.50 with a positive +$0.50 or +0.65% pre-market indication and a 52-week change of +282.43%.

 

The BOTTOM LINE: The witch is driving volatility !

I continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped and  fundamentals are being ignored.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.